540359 PARMAX

Parmax Pharma Share Price

₹45.64 +1.94 (4.44%)

23 Dec, 2024 09:26

SIP TrendupStart SIP in PARMAX

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -0.78%
  • Over 3 Month + 3.49%
  • Over 6 Month + 54.19%
  • Over 1 Year + 38.77%
SIP Lightning

Smart Investing Starts Here Start SIP with Parmax Pharma for Steady Growth!

Invest Now

Parmax Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Parmax Pharma Financials

Parmax Pharma Technicals

EMA & SMA

Current Price
₹45.64
+ 1.94 (4.44%)
pointer
  • stock-down_img
  • Bullish Moving Average 8
  • stock-up_img
  • Bearish Moving Average 8
  • 20 Day
  • ₹46.41
  • 50 Day
  • ₹45.52
  • 100 Day
  • ₹42.78
  • 200 Day
  • ₹39.14

Resistance and Support

45.22 Pivot Speed
  • R3 51.28
  • R2 49.77
  • R1 46.73
  • S1 42.18
  • S2 40.67
  • S3 37.63

What's your outlook on Parmax Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Parmax Pharma has an operating revenue of Rs. 22.68 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of -51% needs improvement, ROE of -8146% is poor and needs improvement. The company has a high debt to equity of 8326%, which can be a reason to worry. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Parmax Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Parmax Pharma F&O

Parmax Pharma Shareholding Pattern

30.8%
62.9%
6.3%

About Parmax Pharma

  • NSE Symbol
  • PARMAX
  • BSE Symbol
  • 540359
  • Managing Director
  • Dr. Umang Alkesh Gosalia
  • ISIN
  • INE240T01014

Similar Stocks to Parmax Pharma

Parmax Pharma FAQs

Parmax Pharma share price is ₹45 As on 23 December, 2024 | 09:12

The Market Cap of Parmax Pharma is ₹17.1 Cr As on 23 December, 2024 | 09:12

The P/E ratio of Parmax Pharma is -5 As on 23 December, 2024 | 09:12

The PB ratio of Parmax Pharma is 210.5 As on 23 December, 2024 | 09:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23